Should you buy Medpace Holdings (MEDP)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Consistent Large Earnings Beats↑Improving
- Compounder Quality Profile↓Deteriorating
- Strong Revenue Growth Trajectory↑Improving
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Large Earnings Beats
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Compounder Quality Profile
Trip ifReturn on equity falls below 50% or Rule of 40 drops below 30 for 2 consecutive reporting periods.
- P3Strong Revenue Growth Trajectory
Trip ifRevenue growth decelerates below 15% year over year for 2 consecutive quarters.
- P4Rich Valuation At Analyst Target
Trip ifForward P/E compresses below 20 times earnings.
- P5Small Biopharma Customer Concentration
Trip ifSmall biopharma customer concentration falls below 70% of revenues.
How the engine reached this verdict
TrendMatrix's engine output for Medpace Holdings, Inc. (MEDP) is STRONG_BUY_WAIT with medium conviction, score 6.5/10 at $608.00. The engine flags WAIT: the structural case holds but the entry-asymmetry math improves at lower prices.
BUY_NOW requires reward-to-risk (NEGATIVE) to clear OR price pulling back to the entry zone of $474.70 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
On the bull side: Strong earnings beat streak (4/4); High-quality business; Strong growth profile. On the bear side: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining; Expensive valuation. Active engine warnings: V8: Target reached (-17.4% upside), V9 Gate Failed: ASYMMETRY:-1.2=NEGATIVE.
The engine's suggested entry zone is $474.70, currently 28.1% above entry. Target $664.34, stop $421.90, asymmetric R:R -1.21. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.5% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates MEDP — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Customer: small biopharmaceutical companies (82.0%)
- ▸Analyst target reached - limited upside remaining
- ▸Expensive valuation